4633 Background: Pazopanib is a small molecule, selective, multi tyrosine kinase inhibitor (TKI), targeting vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R). Pazopanib is approved for the treatment of advanced RCC and is given by oral daily dosing. Other TKIs for this indication… (More)
Figures and Tables
Sorry, we couldn't extract any figures or tables for this paper.